CarThera

[Image from Carthera’s website]Carthera announced today that it enrolled the first patient in the SONOBIRD pivotal trial for its SonoCloud device.

Paris, France-based Carthera designed SonoCloud to treat a wide range of brain disorders. The device emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery.

After implantation in the skull, SonoCloud activates prior to the injection of a therapeutic agent. Several minutes of low-intensity ultrasound opens the blood-brain barrier (BBB) for six hours, increasing the concentration of therapeutic molecules in the brain.

Get the full story at our sister site, Drug Delivery Business News.

[Image from Carthera’s website]Carthera announced today that it closed a $40 million Series B financing round to support its ultrasound-based SonoCloud device.

Paris-based Carthera, a spinoff from Sorbonne University, develops SonoCloud to treat a wide range of brain disorders.

SonoCloud emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery. After implantation in the skull, SonoCloud activates prior to the injection of a therapeutic agent. Several minutes of low-intensity ultrasound opens the blood-brain barrier for six hours, increasing the concentration of therapeutic molecules in the brain.

The system could open up treatment options for a number of indications, including brain tumors and Alzheimer’s disease. Carthera’s SonoCloud-9 system received FDA breakthrough device designation about a year ago.

A prominent, undisclosed investor led the round alongside…

[Image from Carthera’s website]Carthera announced positive results from a trial evaluating the safety and efficacy of the use of its SonoCloud technology.

Results from the investigator-sponsored trial of SonoCloud in patients with mild Alzheimer’s Disease (AD) were published this week in the Alzheimer’s Research & Therapy Journal.

Paris-based Carthera designed SonoCloud, an implantable 1 MHz ultrasound device, to be activated on-demand using a transdermal needle connected to an external interface. The company said in a news release that the platform, which delivers low-intensity pulsed ultrasound (LIPU) to temporarily disrupt the blood-brain barrier (BBB), reduced β-amyloid and tau pathologies and improved cognitive performance in Alzheimer’s preclinical models.

Professor Alexandre Carpentier and Dr. Stéphane Epelbaum conducted a translational study at Hôpital de la Pitié-Salpêtrière (AP-HP Sorbonne, Paris, France) that follows previous tria…

CarThera announced today that it received a $2.3 million (€2 million) grant and $12 million (€10.5 million) in equity, totaling $14.3 million.

Paris-based CarThera was selected by the EIC Accelerator Pilot to receive the funds as it develops its Domeus project for treating glioblastoma patients. In addition to the money, CarThera is also slated to receive business coaching and mentoring through the accelerator, according to a news release.

The company’s Domeus project includes a multicenter, pilot clinical study for its SonoCloud-9 device designed to increase the intracerebral penetration of oncology drugs by transiently opening the blood-brain barrier without increasing dose or subsequent toxicity.

CarThera believes the project will lead to a scale-up in its processes and organizational structure and extend the functionalities of the SonoCloud device. Once completed, the project will transition the company’s status from a clinical-stage to a…